Synthetic Peptide Vaccine Platforms Targeting Tumor-Specific Antigens: Advances and Challenges

  • 3,741

    Total downloads

  • 16k

    Total views and downloads

Submit your idea

Select the journal/section where you want your idea to be submitted:

Submit your manuscript summarySubmit your manuscript

About this Research Topic

Submission closed

Background

It has long been known that tumor-specific antigens (TSAs) that are preferentially expressed on various cancer cells are potentially interesting targets for CD8+ class I epitope targeting. First, unlike neoantigens which result from small changes in expressed DNA, TSAs are generally more immunogenic because they are coded by parts of the exome that are not normally expressed and therefore are seen as more “foreign” by the immune system. Second, because TSAs by definition have very low expression rates on normal tissue, the risk of “off-targeting” by a T-cell attack on normal cells is mitigated.

There are many approved products based on cytotoxic T lymphocytes (CTL) targeting of tumors. These are currently limited to checkpoint inhibitors, that can cause non-specific CTL attacks. Techniques that produce tumor-specific killer T-cell populations using autologous T-cells modified in-vitro (CAR-T) or by incubating autologous T-cells with tumor cells and subsequently re-infusing these T-cells into the patient are also currently used. These approaches require complex manufacturing processes using cell culture and have been associated with significant side effects such as cytokine storm seen with CAR-T therapy. All of the approved products in this space are expensive, potentially further contributing to social inequities in healthcare.

Pre-clinical and clinical studies using a variety of techniques to elicit a CD8+ attack against TSAs such as sequences on HER2 and Survivin (BRIC5) have been reported. Approaches used by investigators to create CTL attacks on TSA class I peptide sequences have ranged from “neat peptides” delivered in combination with various adjuvants including granulocyte stimulating factor and interferons, to “beads on a string” approaches designed to elicit T-cell expansion against tumor antigen targets. Results of these studies have been mixed; lack of a consistent, robust T-cell expansion against the target peptides and not using optimal peptides for CTL attack, may result in these results.

This Research Topic will focus on new tools to predict and evaluate CTL response to TSAs. This will include analysis of synthetic vaccine platforms capable of producing robust CTL expansion against specific class I peptides on TSAs and data showing efficacy using in-vitro tumor cell culture experiments and animal models. We welcome published databases listing class I peptide targeting by cancer patients that could be used to develop and validate TSA CTL targeting tools.

With this Research Topic, we welcome the submission of Original Research, Brief Research Report, Data Report, Technology and Code article types focusing on the use of novel synthetic peptide vaccine platforms that show efficacy against CTL targets on TSAs using in-vitro cell-kill tissue culture experiments or in-vivo using appropriate animal tumor models. The following themes, including but not limited to those in the list below can be included:

- Demonstrating efficacy of specific class I CTL targets on TSAs in cell culture with human tumor cell targeting
- Demonstrating efficacy of specific class I CTL targets on TSAs in cell culture with animal models
- Novel in-vitro / preclinical models for CTL targeting of TSAs
- T-cell response databases of cancer patients cataloging class I targets on TSAs
- Novel computational models predicting optimal targets for CTL attack against TSAs
- Novel synthetic peptide vaccine platforms with demonstrated ability to mount CTL expansion against TSAs.

Please note: Original research based solely on in silico techniques will not be considered for review.

Note on editors: Topic editor Dr. Reid Rubsamen is employed by Flow Pharma, Inc. and Topic Editor Dr. Andrew Sloan works on grant applications with Merck and NIH.

Keywords: Cytotoxic T Lymphocyte, CTL, Tumor Specific Antigen, TSA, peptide vaccine, synthetic vaccine, immunotherapy

Important note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.

Topic editors

Frequently asked questions

  • Frontiers' Research Topics are collaborative hubs built around an emerging theme.Defined, managed, and led by renowned researchers, they bring communities together around a shared area of interest to stimulate collaboration and innovation.

    Unlike section journals, which serve established specialty communities, Research Topics are pioneer hubs, responding to the evolving scientific landscape and catering to new communities.

  • The goal of Frontiers' publishing program is to empower research communities to actively steer the course of scientific publishing. Our program was implemented as a three-part unit with fixed field journals, flexible specialty sections, and dynamically emerging Research Topics, connecting communities of different sizes and maturity.

    Research Topics originate from the scientific community. Many of our Research Topics are suggested by existing editorial board members who have identified critical challenges or areas of interest in their field.

  • As an editor, Research Topics will help you build your journal, as well as your community, around emerging, cutting-edge research. As research trailblazers, Research Topics attract high-quality submissions from leading experts all over the world.

    A thriving Research Topic can potentially evolve into a new specialty section if there is sustained interest and a growing community around it.

  • Each Research Topic must be approved by the specialty chief editor, and it falls under the editorial oversight of our editorial boards, supported by our in-house research integrity team. The same standards and rigorous peer review processes apply to articles published as part of a Research Topic as for any other article we publish.

    In 2023, 80% of the Research Topics we published were edited or co-edited by our editorial board members, who are already familiar with their journal's scope, ethos, and publishing model. All other topics are guest edited by leaders in their field, each vetted and formally approved by the specialty chief editor.

  • Publishing your article within a Research Topic with other related articles increases its discoverability and visibility, which can lead to more views, downloads, and citations. Research Topics grow dynamically as more published articles are added, causing frequent revisiting, and further visibility.

    As Research Topics are multidisciplinary, they are cross-listed in several fields and section journals – increasing your reach even more and giving you the chance to expand your network and collaborate with researchers in different fields, all focusing on expanding knowledge around the same important topic.

    Our larger Research Topics are also converted into ebooks and receive social media promotion from our digital marketing team.

     

  • Frontiers offers multiple article types, but it will depend on the field and section journals in which the Research Topic will be featured. The available article types for a Research Topic will appear in the drop-down menu during the submission process.

    Check available article types here 

  • Yes, we would love to hear your ideas for a topic. Most of our Research Topics are community-led and suggested by researchers in the field. Our in-house editorial team will contact you to talk about your idea and whether you’d like to edit the topic. If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. 

    Suggest your topic here 

  • A team of guest editors (called topic editors) lead their Research Topic. This editorial team oversees the entire process, from the initial topic proposal to calls for participation, the peer review, and final publications.

    The team may also include topic coordinators, who help the topic editors send calls for participation, liaise with topic editors on abstracts, and support contributing authors. In some cases, they can also be assigned as reviewers.

  • As a topic editor (TE), you will take the lead on all editorial decisions for the Research Topic, starting with defining its scope. This allows you to curate research around a topic that interests you, bring together different perspectives from leading researchers across different fields and shape the future of your field. 

     

    You will choose your team of co-editors, curate a list of potential authors, send calls for participation and oversee the peer review process, accepting or recommending rejection for each manuscript submitted.

  • As a topic editor, you're supported at every stage by our in-house team. You will be assigned a single point of contact to help you on both editorial and technical matters. Your topic is managed through our user-friendly online platform, and the peer review process is supported by our industry-first AI review assistant (AIRA).

  • If you’re an early-stage researcher, we will offer you the opportunity to coordinate your topic, with the support of a senior researcher as the topic editor. This provides you with valuable editorial experience, improving your ability to critically evaluate research articles and enhancing your understanding of the quality standards and requirements for scientific publishing, as well as the opportunity to discover new research in your field, and expand your professional network.

  • Yes, certificates can be issued on request. We are happy to provide a certificate for your contribution to editing a successful Research Topic.

  • Research Topics thrive on collaboration and their multi-disciplinary approach around emerging, cutting-edge themes, attract leading researchers from all over the world.

  • As a topic editor, you can set the timeline for your Research Topic, and we will work with you at your pace. Typically, Research Topics are online and open for submissions within a few weeks and remain open for participation for 6 – 12 months. Individual articles within a Research Topic are published as soon as they are ready.

    Find out more about our Research Topics

  • Our fee support program ensures that all articles that pass peer review, including those published in Research Topics, can benefit from open access – regardless of the author's field or funding situation.

    Authors and institutions with insufficient funding can apply for a discount on their publishing fees. A fee support application form is available on our website.

  • In line with our mission to promote healthy lives on a healthy planet, we do not provide printed materials. All our articles and ebooks are available under a CC-BY license, so you can share and print copies.

     

Participating Journals

Impact

  • 16kTopic views
  • 12kArticle views
  • 3,741Article downloads
View impact